Jama Pediatrics published the article, “Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial,” where researchers found that children receiving mepolizumab had reduced type 2 (T2) inflammation while other inflammatory pathways became more prominent during exacerbations compared to the control group. These findings suggest that dampening T2 inflammation may shift the disease process toward alternative mechanisms that still trigger asthma attacks. Understanding the effects of certain drugs on these pathways may help guide the development of more effective treatments for children with acute asthma exacerbations.
Read the full study here.
Read a news article on the study here.